Cambridge Cog Regulatory News (COG)

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Appointment of Chief Operating Officer

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, regrets to announce that, due to a serious medical condition, Nick Kerton, Chief Executive Officer, will be taking an extended leave of absence from the Company.

In Nick's absence, Steven Powell, who has been head of European Operations for the past year, has been appointed Group Chief Operating Officer and will assume the responsibilities of Chief Executive Officer as an interim measure. Steven will join the Board of Directors effective Monday 6th July, 2015.

Steven Powell has over 25 years of operational and investment experience in the pharmaceutical and life sciences sector in research and development, commercial and general management roles. At Cambridge Cognition he has been responsible for building and executing the product development pipeline and establishing the healthcare business unit as well as leading the European operational team.

Michael Lewis, Chairman of Cambridge Cognition, said: "The Board and all at Cambridge Cognition wish Nick all the best in dealing with his illness. We look forward to welcoming him back as soon as he is able to resume his responsibilities. One of Nick's first actions as CEO was to develop a strong and commercially focused senior management team and we are confident that we will be able to continue to deliver to expectations.

"Steven's deep level of involvement in the development and implementation of the current strategy makes him the obvious choice to continue to drive the Company's progress and I am sure that the strength and depth of our wider management team will come to the fore as we continue to grow the business."

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

Steven Powell

Steven John Powell (age 53) is or has been a director or partner of the following companies or partnerships during the previous 5 years:

There is no further information on Dr. Powell required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies.